Evidence map›Paper›PMID 34211176›Full record

ReviewNature reviews. Genetics2021

Genetics of substance use disorders in the era of big data.

Joel Gelernter, Renato Polimanti

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 5 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 5 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Genome-wide meta-analysis of alcohol use disorder in East Asians.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joel GelernterDepartment of Psychiatry, Yale University School of Medicine, West Haven, CT, USA. joel.gelernter@yale.edu.ORCID http://orcid.org/0000-0002-4067-1859
Renato PolimantiDepartment of Psychiatry, Yale University School of Medicine, West Haven, CT, USA.ORCID http://orcid.org/0000-0003-0745-6046
Yale University · US

Funding

Translational Technologies CoreP50AA012870 · NIAAA · YALE UNIVERSITY · PI John H. Krystal · 2001 to 2026
$43.7M
Sex-specific analysis of opioid dependence GWAS and beyondR01DA012690 · NIDA · YALE UNIVERSITY · PI GELERNTER, JOEL · 2000 to 2017
$14.0M
Methamphetamine and Other Substance Use Disorder Genetics in ThailandR01DA037974 · NIDA · YALE UNIVERSITY · PI JOEL GELERNTER, Marc N Potenza · 2015 to 2026
$6.7M
7/7 Psychiatric Genomics Consortium: Finding actionable variationU01MH109532 · NIMH · WASHINGTON UNIVERSITY · PI AGRAWAL, ARPANA, EDENBERG, HOWARD J · 2016 to 2020
$3.1M
Genetics of Alcohol Dependence in African Americans: RecruitmentR01AA026364 · NIAAA · YALE UNIVERSITY · PI GELERNTER, JOEL · 2018 to 2022
$2.0M
Genome-wide Investigation of the Interplay Between Age-Related Hearing Loss and Smoking BehaviorsR21DC018098 · NIDCD · YALE UNIVERSITY · PI POLIMANTI, RENATO · 2019 to 2021
$440k
Investigating the Systems Genetics of the Patterns of Polysubstance Abuse and AddictionR21DA047527 · NIDA · YALE UNIVERSITY · PI POLIMANTI, RENATO · 2019 to 2020
$369k
CSRD VA I01 CX001849NIAAA NIH HHS P50 AA012870NIAAA NIH HHS R01 AA026364NIDA NIH HHS R01 DA012690NIDA NIH HHS R01 DA037974NIDA NIH HHS R21 DA047527NIDCD NIH HHS R21 DC018098NIMH NIH HHS U01 MH109532
6 · The paper itself

Abstract

Substance use disorders (SUDs) are conditions in which the use of legal or illegal substances, such as nicotine, alcohol or opioids, results in clinical and functional impairment. SUDs and, more generally, substance use are genetically complex traits that are enormously costly on an individual and societal basis. The past few years have seen remarkable progress in our understanding of the genetics, and therefore the biology, of substance use and abuse. Various studies - including of well-defined phenotypes in deeply phenotyped samples, as well as broadly defined phenotypes in meta-analysis and biobank samples - have revealed multiple risk loci for these common traits. A key emerging insight from this work establishes a biological and genetic distinction between quantity and/or frequency measures of substance use (which may involve low levels of use without dependence), versus symptoms related to physical dependence.

Indexed as

Genome-Wide Association StudyAlcoholismAnimalsBrainEpigenomicsHumansIllicit DrugsNicotineSubstance-Related DisordersIllicit DrugsNicotine

Identifiers

PMID34211176
PMCPMC9210391
OpenAlexW3175210694

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.